Revenue segments as reported by the company.

Cannabis revenue

Distribution revenue

Beverage alcohol revenue

Wellness revenue

Adult-use

Canada - Medical

International - Medical

Bulk

Hemp

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Impairment of Assets

Litigation settlement

Transaction costs

Change in fair value of contingent consideration

Restructuring costs

Other than temporary change in fair value of convertible notes receivable

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

Tilray Brands

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company with operations in Canada, the United States, Europe, Australia, and Latin America. The firm is focused on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. Its products include dried cannabis and cannabis extracts. It operates through the following segments: Cannabis and Hemp. The Cannabis segment consists of adult-use, medical and bulk sales of cannabis under regulated licenses and sold to retail, wholesale, pharmacy, government, and direct to patient. The Hemp segment consists of hemp seed, hemp foods, and broad spectrum hemp extract containing CBD, which are sold in an unlicensed operation and sold to retail, wholesale and direct to consumers. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

Earnings data Q1 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

Tilray Brands reports record revenue and optimistic outlook for 2025

Tilray Brands achieved remarkable financial performance in Q4 2024, driven by strategic acquisitions and a focus on innovation. Despite challenges like price compression, the company remains optimistic about future growth opportunities. Tilray's commitment to quality products and innovation positions it well for continued success in the market.

Tilray Brands reports record Q1 revenue growth and global expansion

Tilray Brands delivered a robust performance in Q1 2025, showcasing strong revenue growth, margin improvement, and strategic expansion across its diversified product portfolio.
While facing challenges in a competitive landscape and evolving regulatory environment, Tilray's financial strength, international growth initiatives, and focus on innovation position it well for future success.
By capitalizing on opportunities in wellness products, expanding into new beverage categories, and leveraging strategic partnerships, Tilray is poised for continued growth and market leadership.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Tilray Brands, Inc. is a global cannabis-lifestyle and consumer packaged goods company, which focuses on medical cannabis research and the cultivation, processing, and distribution of cannabis products worldwide. It operates through the followings segments: Cannabis Business, Distribution Business, Beverage Alcohol Business, and Wellness Business. The Cannabis Business segment focuses on cultivation, production, distribution, and sale of both medical and adult-use cannabis products. The Distribution Business segment is involved in purchase, resale, and distribution of pharmaceutical and wellness products. The Beverage Alcohol Business segment refers to the production, marketing, and sale of beverages. The Wellness Business segment represents the production, marketing, and distribution of hemp-based food and other wellness products. The company was founded on January 24, 2018 and is headquartered in Leamington, Canada.

CEO Brendan Kennedy's conference call commentary is all the buzz on Wall Street.

Did Tilray's CEO Just Throw In the Towel in Canada?

The cannabis company has a long way to go to catch up.

Tilray Lags Behind Its Marijuana Peers

Nope, it's not the Canadian marijuana producer's soaring revenue nor its widening net loss. It's more critical than both of those numbers.

An Important Detail in Tilray's Q4 Update That You Might Have Missed

The high-flying marijuana company's sales soared last quarter, but its losses are mounting.

The 3 Most Important Takeaways From Tilray's Quarterly Results

When Tilray Inc. released its most recent quarterly results after the markets closed on Monday, the cannabis firm said that it had a net loss of $0.33 per share on $15.5 million in revenue.

What Tilray’s Earnings and Expansion Mean Going Forward

Canadian cannabis producer Tilray reports fourth-quarter earnings after the close today amid questions about recent retail and supply deal.

Tilray To Focus More On U.S., Europe, Tilray Stock Jumps On Earnings

Tilray Inc.  shares gained more than 4% in the extended session Monday after the cannabis producer reported wider-than-expected losses but beat Wall Street revenue estimates.

Cannabis producer Tilray stock rises after losses widen, revenue tops estimates

StoneCo

Del Taco Restaurants

See which stocks are posting big moves after the bell.

After-hours buzz: Tilray, Del Taco Restaurants & StoneCo

Tilray, Inc. (TLRY) CEO Brendan Kennedy on Q4 2018 Results - Earnings Call Transcript

Aurora Cannabis

Canopy Growth

Cronos Group

HEXO Corp

The cannabis industry faces a rare opportunity as the drug heads toward a potential rescheduling in the United States. A new Roth Capital report suggests that multistate operators (MSOs) are the most promising companies in the space.

Roth Sees Rare Opportunity For Cannabis Industry, MSOs

One stock rises and the other declines after market close. Here's why they are making moves.

After-Hours News: Tilray and Del Taco Report Earnings

Tilray shares were jumping in after-hours trading Monday after the Canadian cannabis company reported fiscal fourth-quarter and full-year financial results. 

Tilray Reports EPS Miss, Sales Beat In First Quarterly Print Since Canadian Cannabis Legalization

The Canadian producer's bottom line worsened during the first quarter of legalized marijuana sales.

Tilray Posts Fourth Quarter Earnings Miss as Revenue Soars

In the cannabis space, there are a number of players, some older but many newer, that have come out of obscurity over the years.

Tilray, Inc: A Truly Viable Cannabis Play

Ford Motor Company

Markets were higher as the week came to a close.

Stock Market News: Ford Builds Suspense; Will Tilray Go to Pot?

Tilray Inc.  on Wednesday announced the expansion of its global senior leadership team.

Tilray Adds Former Goldman Sachs Managing Director To Senior Management Team

Wall Street is beginning to weigh in on the marijuana industry, and investors may not like what they hear.

3 Pot Stocks Wall Street Thinks You Should Sell

Tilray looks like an underperformer in the eyes of one analyst. Is he right?

3 Reasons 1 Top Analyst Gives a Thumbs-Down to Tilray

A comprehensive look at the share price where marijuana stock Tilray would offer intriguing value for investors.

At What Price Is Tilray Worth Buying?

Aphria

GW Pharmaceuticals

Therapix Biosciences

Zynerba Pharmaceuticals

There is a lot of hype regarding CBD and a lack of regulatory clarity. I discuss the big issues and identify some of the better players in the space among public-traded companies.

Investing In CBD Stocks Offers Opportunity But Risks

Amazon prospered while most dot-com era companies flopped. Could one of these top marijuana stocks be a similar success story?

Aurora Cannabis, Canopy Growth, or Tilray: Which Stock Will Be the Amazon of the Marijuana Boom?

The analyst blasts Canadian pot star as "arguably inferior" and "too expensive."

Jefferies: Not a Ray of Hope for Tilray

Shares of cannabis company Tilray Inc. fell 7% in premarket trade Friday, after the cannabis stock was initiated with an underperform rating by Jefferies, saying it struggles to justify its current valuation.

UPDATE: Tilray shares fall 7% premarket as Jefferies initiates coverage with underperform rating

Shares of cannabis company Tilray Inc.  fell 3.9% in premarket trade Friday, after the cannabis stock was initiated with an underperform rating by Jefferies, saying it struggles to justify its current valuation.

Tilray shares fall 3.9% premarket as Jefferies initiates coverage with underperform rating

The news has sparked countless conversations between investors and entrepreneurs about what the deal means for the legal hemp industry, especially in the absence of meaningful guidance by the United States Food and Drug Administration (FDA) about how to regulate cannabidiol (CBD).

News for Tilray Brands Stock (TLRY)